Treatment with lixisenatide, a medication approved for type 2 diabetes, significantly slowed the progression of motor symptoms in people with Parkinson’s disease in a Phase 2 clinical trial. Although gastrointestinal side effects such as nausea and vomiting were more common with the therapy, the findings support lixisenatide as a potential…
News
Scientists at the French Alternative Energies and Atomic Energy Commission (CEA) released the first images of a live human brain acquired with the world’s most powerful MRI scanner, the Iseult MRI machine. “With the Iseult project, a whole new world is opening up before our eyes, and we are excited…
A five-year project funded by a National Institutes of Health (NIH) research grant totaling nearly $1.9 million will study amyloid fibrils, protein clumps that are a hallmark of Parkinson’s disease and other neurodegenerative conditions. This work may shed new light on the disease-causing mechanisms related to these fibrils —…
People with REM sleep behavior disorder, a condition that often precedes Parkinson’s disease, frequently have mitochondrial DNA (mtDNA) damage, a study found. “Patients with REM sleep behavior disorder, both those who subsequently developed Parkinson’s disease and those who did not, had more mitochondrial DNA circulating in the cerebrospinal fluid…
Fecal microbiota transplant, a procedure that works to replace a person’s gut bacteria with gut bacteria from a healthy donor, may help ease motor symptoms of Parkinson’s disease, a small clinical trial found. Transplant “offers the advantages of being considered safe based on experience in other indications, and being…
Manifest Technologies has completed initial funding and a partnership with Johnson & Johnson to apply its artificial intelligence (AI)-powered platform toward developing precision treatments for neurological diseases, including Parkinson’s disease, the company announced. The NAIO (Neuroscience and Artificial Intelligence Optimized) platform integrates neuroimaging data from humans and…
A 3D-printed, high-resolution model of the brain has been developed that will offer a promising tool for advancing research into neurodegenerative conditions such as Parkinson’s disease. Dubbed a “brain phantom,” the models were made to mimic the small structural details of nerve cells in the brain, but they aren’t…
NeuroOne has begun a limited U.S. commercial launch of its OneRF Ablation System, a device that can be used for mapping and targeting brain areas with abnormal neuronal activity to treat a range of neurological conditions such as Parkinson’s disease. The company said it’s rolling out the…
The focus of this year’s Parkinson’s Awareness Month, starting today, is on research and a better understanding of the neurodegenerative disorder that affects more than 10 million people globally. World Parkinson’s Day on April 11 is at the center of the observance. Parkinson’s disease can cause a broad array…
Defects in the VPS13C protein, which have been linked to early-onset Parkinson’s disease, disrupt the function of lysosomes, the cell’s recycling compartments, in dopamine-producing nerve cells that are lost in the neurodegenerative condition. Without functional VPS13C, the Rab10 protein can’t respond properly to lysosomal stress, causing dysfunction in the…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s